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Pulsing with blast cell lysate or blast-derived total RNA
reverses the dendritic cell-mediated cytotoxic activity of
cytokine-induced killer cells against allogeneic acute
myelogenous leukemia cells
Pulsen mit Blastenzelllysat oder Blasten-Gesamt-RNA richtet die durch
dendritische Zellen vermittelte Aktivität von Zytokin-induzierten
Killerzellen gegen allogene akute myeloische Zellen
Abstract
Immunotherapeutic strategies may be a treatment option in patients
with refractory acute myelogenous leukemia (AML) or, in cases of
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2 complete remission after conventional therapy regimens, may help to
reduce disease recurrence or delay time to progression. Evidence sug-
gests a key role of dendritic cells (DCs) in cancer immunotherapy due
to their capacity to present tumour antigens to effector cells. We gener- 1 Medizinische Klinik und
PoliklinikII,Universitätsklinik ated cytokine-induced killer (CIK) cells from healthy donors and ex-
amined their responses in vitro in an LDH release assay against three Würzburg, Würzburg,
Germany cell lines and allogeneic HLA non-matched blasts from three patients
with de novo AML after coincubation with autologous peripheral blood 2 Medizinische Klinik und
Poliklinik III, Rheinische monocyte-derived DCs. Although DCs were unable to enhance CIK cell
effects against all three cell lines tested, the cytotoxic activity against Friedrich-Wilhelms-
Universität, Bonn, Germany thepatients’AMLcellsincreasedaftercoculturewithmatureDCs,which
was significant in two of three patients. However, neither prior pulsing
of the DCs with blast cell lysates nor with leukemic cell-derived total
RNAfurtherenhancedthelyticcapacityoftheCIKcells.Onthecontrary,
pulsing reduced or even reversed the cytotoxic activity of the effector
cells. This decrease of allogeneic cytotoxicity led us to conclude that
monocyte-derivedDCsmaybeusefulinautologousorallogeneicvaccine
strategies for the treatment of AML or in priming donor lymphocytes in
vitro,butunfractionatedantigensaspulsingagentsmayhaveinhibitory
effectsonTcellefficiencyandtheiremploymentinimmunotherapeutic
strategies for AML seems questionable.
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Zusammenfassung
Immuntherapeutische Strategien können eine Behandlungsoption bei
PatientenmitrefraktärerakutermyeloischerLeukämie(AML)seinoder
in den Fällen einer kompletten Remission nach konventionellen Thera-
pieformen helfen, das Wiederauftreten der Krankheit zu verhindern
oderdieZeitbiszurProgressionzuverlängern.EsgibtHinweisedarauf,
dass dendritische Zellen (DCs) eine zentrale Rolle in der Krebs-Immun-
therapiespielenaufgrundihrerFähigkeit,tumorantigeneEffektor-Zellen
zu präsentieren. Wir stellten Zytokin-induzierte Killer (CIK)-Zellen von
gesunden Spendern her und untersuchten deren Reaktionen in vitro
ineinemLaktatdehydrogenase(LDH)-AssaygegenZelllinienundallogene
HLA nicht übereinstimmende Blasten von drei Patienten mit de novo
AML nach Koinkubation mit autologen aus dem peripheren Blut abge-
leiteten DCs. Obwohl DCs die CIK Zellen Wirksamkeit gegen alle drei
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Research Article OPEN ACCESSgetesteten Zelllinien nicht verbessern konnten, wurde die zytotoxische
Aktivität gegen die Patienten-AML-Zellen nach Kokultur mit reifen DCs
in zwei von drei Patienten signifikant erhöht. Doch weder ein Pulsen
der DCs mit blastären Zelllysaten noch mit aus leukämischen Zellen
gewonnenerGesamt-RNAkonntendielytischeKapazitätderCIK-Zellen
weiter verbessern. Im Gegenteil, gepulste DCs reduzierten sogar die
zytotoxischeAktivitätderEffektorzellen.DieserRückgangderallogenen
ZytotoxizitätführteunszudemSchluss,dassvonMonozytenabgeleitete
DCs nützlich sein könnten in autologen oder allogenen Impfstrategien
zur Behandlung von AML. Unfraktionierte Antigene zum Pulsen von DC
können dagegen hemmende Wirkung auf T-Zellen haben.
Schlüsselwörter: dendritische Zellen, Zytokin-induzierte Killerzellen,
AML, Zelllysat, RNA
Introduction
Chemotherapy and allogeneic bone marrow transplanta-
tion (BMT) are conventional options for the treatment of
acute myelogenous leukemia (AML) [1], [2], [3], [4]. Al-
though complete remissions can be achieved in the ma-
jority of patients, relapse of the disease remains a fre-
quent cause of treatment failure and results in a poor
prognosis[5].Therapeuticoptionsforpatientswithrecur-
rent leukemia are limited. After BMT, second marrow
transplantsfromthesamedonormaybeconsidered,but
the mortality, treatment-related morbidity and risk of
further relapse are high [6], [7].
Alternativeoradditionalstrategiesareprovidedbyimmun-
otherapeutic approaches. The importance of T cell reac-
tions against leukemic cells is demonstrated by the suc-
cessful employment of donor lymphocyte infusions (DLI)
in patients with relapsed chronic myelogenous leukemia
(CML) after allogeneic BMT. The application to acute
leukemiapatientsalsoshowssusceptibilityofAMLblasts
to the donor lymphocytes, though the treatment turns
out to be less effective [8], [9], [10], [11].
In solid tumours, antigen-specific immunotherapy has
already emerged as a promising approach to control the
disease. Evidence suggests the central role of dendritic
cells(DCs)formediatingtheseimmunereactions,asthey
are specialized to prime naive helper and cytotoxic
T lymphocytes and directly trigger NK cell functions [12],
[13],[14],[15].DCscanstimulateTcellsastheyexpress
high levels of major histocompatibility complex (MHC)
class I and II molecules along with costimulatory mol-
ecules such as B7.1 (CD80) and B7.2 (CD86) on their
surface. They are equipped to capture and process anti-
gens – e.g., tumour-associated antigens – and present
immunogenic MHC-peptide complexes to T lymphocytes
and so enhance the otherwise low immunogenicity of
these proteins [16], [17], [18], [19]. Mature DCs migrate
to secondary lymphoid organs where they stimulate anti-
gen-specific T cells [20].
Hence, the use of DCs in vaccine strategies for the
treatment of malignancies promises to be helpful to
overcome the resistance of tumours to the immune sys-
tem. For this purpose, active DCs can be generated ex
vivo in large quantities. In fact, several studies have
demonstrated tumour responses after vaccination with
antigen-pulsed DCs in a variety of mouse tumour models
andeveninhumanmelanoma,non-Hodgkin’slymphoma
(NHL) and prostate cancer [21], [22], [23], [24], [25].
Vaccine strategies may use DCs prepared with either
defined tumour-associated antigens such as HPV-16
E6/E7 [26], [27] or proteins of the MAGE family in
melanoma patients [28], or with undefined tumour anti-
gens such as whole tumour lysates [24], [25] or tumour-
derived total RNA [29]. The use of whole tumour lysate
orcompleteRNAincancerimmunotherapyprovidessome
advantages as compared with the use of defined tumour
antigens: The identification of the effective antigen(s) is
not required and treatment strategies are feasible even
for malignancies (such as AML) in which only few more
or less specific tumour-associated antigens have been
characterized [30], [31]. Furthermore, the probable
presence of multiple antigens reduces the risk of a tu-
mour cell escape [32]. Finally, in patients with acute
leukemia tumour material required for the generation of
lysate or RNA can easily be obtained in sufficient quan-
tities from peripheral blood or bone marrow aspirates.
Onemajordrawbackintheuseofunfractionatedantigens
is the possible occurrence of autoimmune reactions dir-
ected against ‘self-antigen’ included in the lysate or total
RNA [33], [34].
Inthisstudy,weusedperipheralbloodmonocyte-derived
DCs from healthy donors pulsed with either whole blast
cell lysate or blast cell-derived total RNA to stimulate
autologous cytokine-induced killer (CIK) cell responses
invitroagainstthreeAMLcelllinesandagainstallogeneic
blasts from three HLA-unmatched patients with de novo
AML.
Materials and methods
AML cells
AML cell lines HL-60, KG-1 and the CML cell line K-562
(chronic myelogenous leukemia in blast crisis) were pur-
chased from the Deutsche Sammlung für Mikroorganis-
men und Zellkultur (DSMZ, Braunschweig, Germany).
Peripheral blood from patients (Table 1) at de novo
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afterinformedconsentinaccordancewithourlocalethic
committee. Cells were isolated by Ficoll density gradient
centrifugationandmaintainedinRPMI1640(GibcoBRL,
Berlin,Germany)supplementedwith10%FCS(PAA,Linz,
Austria), 100 U/mL penicillin and 100 µg/mL strepto-
mycin (Biochrom, Berlin, Germany). Patients’ AML cells
could be maintained for 6 to 35 d.
Table 1: Characteristics of AML patients
Dendritic cells
Peripheralbloodmononuclearcells(PBMC)wereisolated
from healthy donors’ buffy coats (day 0) by Ficoll density
gradient centrifugation (Lymphoprep, Nycomed, Oslo,
Norway). Cells were allowed to adhere in six-well-plates
(Becton Dickinson, Heidelberg, Germany) at a density of
5 x 10
6 cells/mL for 1 hr at 37°C in a humidified atmos-
phere of 5% CO2 in RPMI 1640 medium with 10% auto-
logous serum. Non-adherent cells were collected for
generating cytotoxic lymphocytes (see below). Adherent
monocytes were cultured in 2 mL RPMI 1640 with 10%
autologousserum,25mMHepes(hydroxyethylpiperazine
ethanesulfonicacid),100U/mLpenicillinand100µg/mL
streptomycin supplemented with 750 U/mL human
granulocyte-macrophage colony-stimulating factor (GM-
CSF) and 500 U/mL human interleukin-4 (IL-4, Essex
Pharma, Nürnberg, Germany) for 7 d. Medium was
changedonday4and500U/mLtumournecrosisfactor-α
(TNF-α) was added on day 5.
To generate DCs from leukemic blasts, patients’ AML
cellswereisolatedandculturedasdescribedabove.Only
samplescontainingmorethan65%leukemicblastswere
used. GM-CSF, IL-4, and TNF-α were repetitively added
at the above mentioned concentrations every 3 to 4 d.
Medium was changed when necessary.
Effector cells
Effector cells, termed cytokine-induced killer cells (CIK
cells), were generated as described previously [35].
Briefly,non-adherentFicollseparatedhumanPBMCwere
grown in RPMI 1640 medium consisting of 10% fetal calf
serum, 25 mM Hepes, 100 U/mL penicillin and
100 µg/mL streptomycin (hereafter referred to as com-
pletemedium)intissuecultureflasks(BectonDickinson)
and incubated at 37°C in a humidified atmosphere of
5%CO2at3x10
6cells/mL.1,000U/mLhumanrecombin-
ant interferon-γ (IFN-γ, Roche, Mannheim, Germany) was
added immediately (day 0). After 24 hrs of incubation,
50ng/mLofanantibodyagainstCD3(OrthocloneOKT-3,
Cilag GmbH, Sulzbach, Germany), 100 U/mL IL-1β and
300 U/mL IL-2 (Roche) were added. IL-2 was used for
repetitive stimulation every 3 to 4 d at a concentration
of 300 U/mL. Fresh medium was added when required.
Additionally, for comparing different effector cell types,
peripheral blood lymphocytes (PBLs) and lymphokine-
activated killer cells (LAK cells) were generated from
cryopreserved non-adherent Ficoll separated human PB-
MC. PBLs were thawed 1 d before use and grown within
complete medium without cytokines, LAK cells were
generated by thawing 6 d before use and culturing within
complete medium supplemented with IL-2 (1,000 U/mL)
[36].
Phenotypic analysis of cells by flow
cytometry
Cells were washed with PBS and single cell suspensions
were stained with various combinations of fluorescein
isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated
mouse antihuman monoclonal antibodies in a total
volume of 50 µl for 15 min on ice. Stained cells were
washed with PBS and flow cytometric analysis was sub-
sequently performed on a Coulter Epics XL Cytometer
(Coulter-Immunotech, Krefeld, Germany). Background
staining using FITC- and PE-conjugated mouse IgG was
<2%.Datafrom20,000cellswerecollectedandanalyzed.
DCs were phenotyped with the following markers: CD14,
CD80,CD83(Coulter-Immunotech),CD86,HLA-ABC,and
HLA-DR(Pharmingen,Hamburg,Germany).Effectorcells
were analyzed for the expression of the phenotypic
markersCD3,CD4,CD8,CD28,andCD56(Coulter-Immu-
notech).Phenotypiccharacterizationofthepatients’AML
cells was performed with monoclonal antibodies against
CD14, CD80 (Coulter-Immunotech), CD13, CD64, CD86,
HLA-ABC, HLA-DR (Pharmingen), and CD34 (Becton
Dickinson).
Isolation of blast cell lysates and RNA
AML cell lines and patients’ samples containing more
than65%leukemicblastswereused.Patients’AMLcells
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de novo leukemia stage and cultured in RPMI 1640
supplemented with 10% FCS. Cells were harvested,
washedwithphosphate-bufferedsaline(PBS,PAA,Cölbe,
Germany) and alternately frozen in liquid nitrogen and
thawed at 37°C five times. The blast cell extract solution
was filtered (0.2 µm) and protein concentration was
measured using a Bradford protein assay (Bio-Rad, Mu-
nich, Germany). The protein solution was then stored at
–20°C until used in DC-pulsing experiments.
Total RNA from leukemic blasts was extracted using the
RNeasy Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. After isolation, the RNA was re-
constituted in sterile, endotoxin- and RNase-free water
and quantitated by measuring OD at 260 and 280 nm.
OD 260/280 ratios were typically 1.65-2.0. RNA was
stored at –70°C.
Pulsing of DCs
Blast cell-derived lysate at various concentrations was
addedtotheDCsonday1.Antigenexposurewasstopped
after 4 hrs by medium replacement or on day 4 when the
medium was changed routinely.
Pulsing with tumour-derived RNA was performed on day
2 in serum-free RPMI 1640 medium. The cationic lipo-
some DOTAP (N-[1-(2,3-Dioleoyloxy)]-N,N,N-trimethyl-
ammonium propan methylsulfate, Roth) was employed
totransfertheRNAintotheDCs.VariousamountsofRNA
and DOTAP were mixed in a constant ratio of 1 µg RNA
to 2 µl transfectant at room temperature for 15 min, but
notmorethan8µlDOTAPwereusedevenfortransfection
with the highest RNA concentrations due to toxic effects.
ThecomplexeswereaddedtotheDCsin500µlofserum-
free medium, and the cells were slightly shaken at 37°C
for1hr.Serum-freemediumwasaddedtoafinalvolume
of2mL,andtheDCswereincubatedat37°Cinahumid-
ified atmosphere of 5% CO2. Pulsing was stopped after
24 hrs by adding 10% autologous serum to the medium.
Replacement of medium and addition of TNF-α were
performed as described above.
Coculturing of effector cells with DCs
Lymphocytes were harvested on day 7 and cocultured
withautologousDCsfor7dusingstimulatortoresponder
ratiosof1:5to1:10whichhadbeenfoundtobeoptimal.
IL-2wasaddedimmediatelyorupto48hrsaftercoincub-
ation and once again 3 d later.
Cytotoxicity assay
A CytoTox 96 non-radioactive assay (Roche) was used to
measure cytotoxic activity. This enzymatic assay quanti-
tatively measures lactate dehydrogenase (LDH) which is
released upon cell lysis and has been shown to be of
identical efficiency as compared to standard
51[Cr] chro-
mium release assay [37], [38]. Target cells (cell lines or
AMLpatients’allogeneicblasts)wereplatedintriplicates
in a 96-well U-bottom tissue culture plate (10
4 cells/well)
and coincubated with lymphocytes at final effector to
target cell ratios of 2.5:1, 5:1, 10:1 and 20:1. After
4.5 hrs of incubation, cells were centrifuged and 50 µl
supernatant from each well was transferred to a fresh
96-well plate, 50 µl of the substrate mix was added and
incubated at room temperature in the dark for 15 to 30
min.Beforemeasuring,50µlofastopsolutionwasadded
to each well. Maximal release of LDH was performed by
incubating the target cells with 0.1% anionic detergent
(IGEPAL, Sigma, Deisenhofen, Germany). Target cells
without effector cells were used as negative control
(spontaneous release). Absorbency data were collected
at 490 nm using a 96-well plate reader. Cytotoxicity was
calculated according to the following formula:
whereETistheexperimentalrelease,Espontisthespontan-
eous release by effector cells, Tspont is the spontaneous
release by target cells, and Tmax is the maximal release by
target cells.
Statistical analysis
Wilcoxon’s signed rank test was used to analyze for
statisticalsignificance.APvalueof<0.05wasconsidered
significant.
Results
Flow cytometric analysis of DCs
DCs were generated from monocytes using GM-CSF, IL-4
andTNF-αasdescribedin“Materialsandmethods”.After
7 d of culture the yield of cells was 0.4-1 x 10
6/well and
flow cytometric analysis revealed 94.7±2.4% of the cells
expressing CD80, 39.6±4.4% CD83, 85.3±2.7% CD86,
98.5±2.1% HLA-ABC and 96.4±3.1% HLA-DR while
68.4±7.0%ofthecellswerenegativeforCD14(Figure1).
These data represent the mean ± standard error of the
mean (SEM) of five separate experiments. Pulsing of the
DCs with blast cell lysate (10 µg/mL) or total RNA
(10µg/mL)didnotalterthepercentageofMHCmolecule,
CD80, CD86 or CD83 expression (data not shown).
OnDCsgeneratedfromthepatients’leukemicblastswith
GM-CSF, IL-4 and TNF-α, flow cytometric analysis was
performed when >60% of the cells showed typical DC
morphology (between days 11 and 21). The flow cyto-
metricphenotypeofthecellswascomparedtoautologous
leukemic blasts cultured for equivalent periods without
cytokines (see below). Cells developed or upregulated
expression of costimulatory and MHC molecules, but the
percentage varied strongly from patient to patient, and
CD83 expression did not exceed 20% in any of the three
patients (data not shown).
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Schöttker et al.: Pulsing with blast cell lysate or blast-derived total ...Figure 1: Flow cytometric analysis of monocyte-derived DCs from healthy donors
DCs were generated and cultured as described in “Materials and methods”. On day 7, cells were stained with monoclonal
antibodies against CD80, CD83, CD86, HLA-A,B,C, HLA-DR, and CD14 and analyzed. One representative of five experiments is
illustrated.
Flow cytometric analysis of CIK cells
The effector cell population was generated as described
in“Materialsandmethods”usingIFN-γ,antibodyagainst
CD3, IL-1ß, and IL-2. Results of the flow cytometric ana-
lysis are shown in Figure 2. From day 1 to day 14 of cul-
ture, CD3 expression increased from 73.5±2.5% to
94.5±3.4%. Co-expression of CD3 and the costimulatory
signal CD28 remained unchanged (day 1: 68.0±5.5%;
day 14: 71.4±6.3%). While 42.5±11.2% of the cells were
positiveforCD8onday1and66.5±2.7%onday14,CD4
expression decreased from 36.3±9.4% to 28.9±4.4%,
resulting in a mean CD8
+ to CD4
+ cell ratio of 2.3 on day
14ascomparedto1.2onday1.Cocultureoftheeffector
cell population with DCs on day 7 led to a further but not
significant increase in this ratio on day 14 (data not
shown).PercentageofCD3
+CD56
+cellswas<3.2%(mean
of 1.9%) on day 1 and ranged from 5.1% to 14.3% (mean
of 7.2%) on day 14. Data represent the mean ± SEM of
five separate experiments.
MHC and costimulatory molecule
expression on AML cells
Phenotypic analysis of AML cells derived from patients is
shown in Table 1. Blast cells were HLA-ABC
+HLA-
DR
+CD80
-CD86
- in patients 1 and 2, and HLA-ABC
+HLA-
DR
-CD80
-CD86
-inpatient3.HL-60,KG-1,andK-562cells
were HLA-ABC
+HLA-DR
-, HLA-ABC
+HLA-DR
+, and HLA-
ABC
-HLA-DR
-, respectively, while all cell lines were CD80
-
CD86
- (data not shown).
CIK cell activity in comparison to PBLs
and LAK cells
First, we determined the basic allogeneic cytotoxicity of
the CIK cell population in comparison to PBLs and LAK
cells against myeloblastic cells from one AML patient
chosen representatively. For this purpose, we performed
anLDH-releaseassaywiththedifferenteffectorcelltypes
generated from three healthy donors, using AML cells
from patient 2 as target cells. At an effector to target cell
ratio (E:T ratio) of 20:1 mean blast cell lysis in three
separateexperimentswas3.4%,17.0%and25.3%using
PBLs, LAK cells and CIK cells, respectively (Figure 3),
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Effector cells were cultured as described in “Materials and methods”. On days 1, 8 and 14 cells were stained with monoclonal
antibodies against CD3, CD4, CD8, CD28 and CD56 and analyzed. Results are presented as mean values ± SEM from five
independent experiments.
Figure 3: Cytotoxic activity of PBLs, LAK cells and CIK cells against leukemic blasts from one patient with AML (patient 2)
The distinct effector cells were generated from healthy donors according to the protocols described in “Materials and methods”.
Lysis was measured by an LDH-release assay. PBLs were used on day 1, LAK cells on day 6 of culture, CIK cells had been grown
for 14 d. Results represent the mean of three independent experiments (SEM <20% of the mean).
which led us to perform the following studies with the
latter effector cell population.
EffectorcellcytotoxicityagainstAMLcell
lines
CIK cells from healthy donors were cocultured with auto-
logous either non-pulsed DCs or blast cell lysate- or total
RNA-pulsed DCs and tested for cytotoxicity against cell
lines HL-60, KG-1 and K-562. Successful delivery of RNA
into DCs was demonstrated by flow cytometric analysis
24hrsaftertransfectionofthecellswithenhancedgreen
fluorescent protein RNA (eGFP-RNA) using DOTAP. Mean
transfection efficiency was 15% as determined by evalu-
ating the percentage of positive cells in a flow cytometric
analysis (data not shown). Toxic effects of DOTAP on the
DCs were excluded by adding 8 µl of the transfectant to
non-pulsed DCs before coincubation with CIK cells which
did not result in a decrease of effector cell number or
cytotoxicity.
Coculture with DCs led to a 1.5–3.5fold increase in
lymphocyte count, and no difference was detectable
between cultures with pulsed and non-pulsed DCs.
Lymphocytes proliferated preferably in the vicinity of DC
clusters. In Figure 4, the cytotoxicity of the effector cell
population against the three different cell lines is
demonstrated. At an E:T ratio of 20:1, a mean of 24.4%
of HL-60 cells, 9.3% of KG-1 cells and 18.6% of K-562
cells were lysed by effector cells that had not been coin-
cubatedwithDCs.Neithercoculturewithnon-pulsedDCs
nor with DCs that had been pulsed with blast cell lysate
or RNA could increase the cytotoxicity significantly.
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Schöttker et al.: Pulsing with blast cell lysate or blast-derived total ...Figure 4a–c: Cytotoxic activity of T cells against cell lines HL-60 (a), KG-1 (b) and K-562 (c)
CIK cells and DCs were generated from various healthy donors as described in “Materials and methods”. Effector cells were
cocultured on day 7 with either non-pulsed DCs or with DCs that had been exposed to blast cell lysates or AML cell-derived RNA,
respectively. Lysis of AML blasts was measured in an LDH-release assay on day 14 of cell culture. Effector cells not coincubated
with DCs were used as control. (EC, effector cells (control); EC/DC, effector cells cocultured with non-pulsed DCs; EC/DC/lysate,
effector cells cocultured with DCs pulsed with blast cell lysate; EC/DC/RNA, effector cells cocultured with DCs pulsed with blast
cell-derived total RNA). Results represent the mean of at least three separate experiments (SEM <20% of the mean).
Effector cell cytotoxicity against blast
cells derived from AML patients
To investigate the allogeneic activity of CIK cells derived
fromhealthydonorsagainstmyelogenousleukemicblasts
from patients with AML, we performed an LDH-release
assayonday14ofCIKcellcultureandusedmyeloblastic
cells from three separate patients as targets. CIK cells
were cocultured with autologous either non-pulsed DCs
or with DCs that had been stimulated with the respective
blast cell lysates or leukemic cell-derived total RNA. Ef-
fectorcellsnotcoculturedwithDCswereusedascontrol.
The increase in CIK cell number ranged from 1.5-4.0fold
after coculture with DCs, independent of prior pulsing.
For patients 1, 2 and 3, the basic CIK cell activity at an
E:Tratioof20:1increasedfrom8.1%to22.6%(p=0.043),
from 18.7% to 48.3% (p=0.028) and from 29.4% to
32.8% (p>0.05), respectively, after coincubation with
non-pulsed DCs (mean of at least four experiments; SEM
<20% of the mean), as shown in Figure 5.
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Schöttker et al.: Pulsing with blast cell lysate or blast-derived total ...Figure 5a–d: Allogeneic antileukemic CIK cell activity against AML blasts derived from three different AML patients
CIK cells and DCs were generated from different healthy donors as described in “Materials and methods”. Effector cells were
cocultured on day 7 with either non-pulsed DCs or with DCs that had been exposed to the respective blast cell lysates or AML
cell-derived total RNA. Lysis of AML blasts was measured using an LDH-release assay on day 14 of cell culture. Effector cells not
coincubated with DCs were used as control. (EC, effector cells (control); EC/DC, effector cells cocultured with non-pulsed DCs;
EC/DC/lysate, effector cells cocultured with DCs pulsed with blast cell lysate; EC/DC/RNA, effector cells cocultured with DCs
pulsed with blast cell-derived total RNA). Results represent the mean of at least four independent experiments (SEM <20% of
themean).Thedifferencebetweencontrolandeffectorcellscoculturedwithnon-pulsedDCsatanE:Tratioof20:1wassignificant
for patient 1 and 2 (p=0.043 and p=0.028, respectively).
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diated increase in the antileukemic CIK cell effect be
further enhanced by prior pulsing of the DCs with the re-
spective antigens. On the contrary, in patient 1 the DC-
mediated effect remained unchanged or was even re-
duced – if not reversed – by using DCs pulsed with vari-
ousconcentrationsoflysateorRNA(Figure5a).Inpatient
2, the decrease of blast cell lysis after coculture with
pulsed DCs was antigen concentration-dependent as
demonstrated in Figure 5b+c. Coincubation of effector
cells with lysate-pulsed monocyte-derived DCs resulted
in a decrease of target cell lysis to 22.9% using 1 µg/mL
lysate and to 9,0% using 10 µg/mL lysate at an E:T ratio
of20:1(Figure5b).Lysisofthesamepatient’sblastcells
byCIKcellscoincubatedwithRNA-pulsedDCswas49.5%,
39.3%, 13.5% and 12.0% using 1.25 µg/mL, 2.5 µg/mL,
5µg/mLor10µg/mLRNA,respectively(Figure5c).Lower
antigenconcentrationsthanthoseindicateddidnotinflu-
encetheDC-mediatedeffectontheeffectorcells.Results
represent the mean of at least four independent experi-
ments (SEM <20% of the mean). For this patient, suffi-
cient amounts of DCs derived from autologous leukemic
blasts could be generated and were used comparatively.
Mean target cell lysis at an E:T ratio of 20:1 was 48.3%
using CIK cells cocultured with autologous, non-pulsed
monocyte-derived DCs (see above) and 46.1% using CIK
cells cocultured with autologous blast-derived DCs, indi-
catingtheequivalenteffectofDCsofbothorigins.Finally,
the antileukemic effect of allogeneic CIK cells against
blast cells derived from patient 3 was diminished to two
thirds or less of baseline levels with the strongest reduc-
tionappearingwhen10µg/mlRNAwereused(Figure5d).
In all experiments, neither the period of time DCs were
exposed to antigen nor the time point of IL-2 addition to
the effector cells during coculture had influence on the
effects described.
Discussion
In this study, we generated CIK cells from various HLA
non-matchedhealthydonorsthatexhibitedconsiderable
cytotoxicity against two of three cell lines tested (HL-60
andK-562)andallogeneiccytotoxicactivityagainstblast
cellsderivedfromthreeAMLpatients.Wecouldenhance
the capacity of these CIK cells to lyse the patients’ leu-
kemiacellsusingautologous,peripheralbloodmonocyte-
derived DCs for coincubation with the effector cells,
whereasnoincreaseinactivitycouldbeobservedagainst
allthreecelllines.Neitheremploymentofblastcelllysate
nor leukemic cell-derived total RNA for pulsing the DCs
led to a further increment of target cell lysis. On the con-
trary, either antigens mostly reduced or even reversed
the cytotoxic activity of the effector cell population.
Antileukemic activity of CIK cells
The effector cell population generated for our experi-
ments,termedcytokine-inducedkillercells(CIK),consists
of up to 15% CD3
+CD56
+ cells which are rarely found in
theperipheralblood.CIKcellshavebeenshowntoexhibit
enhancedcytotoxicactivityandtoproliferatemorerapidly
than LAK cells [35], [39], [40]. As compared with other
lymphocyte populations used for cytotoxicity studies with
patients’ AML cells, CIK cells showed basic lytic activity
that was considerably high (8.1%, 18.7% and 29.4%) at
comparably low E:T ratios (20:1). For example, LAK cells
fromhealthydonorsandpatientswithAMLshowed<15%
mean target cell lysis against autologous and allogeneic
myeloblastic leukemia cells at an E:T ratio of 60:1, and
unactivated control lymphocytes lysed <5% of the same
targets [36]. This discrepancy between the distinct
lymphocyte populations was confirmed by our own stud-
ies. It apparently depends, on the one hand, on the
amountofCD56
+–i.e.,non-MHC-restricted–cellswithin
the respective population. On the other hand, although
CIK cells appeared to be more effective than LAK cells
lysing one representative patient’s AML blasts in our ex-
periments, natural killer (NK) cell-sensitive K-562 cells
were lysed to a lower extent (18.6%) as compared to ap-
proximately 50% of K-562 cells lysed by LAK cells at an
E:Tratioof20:1[41].Hence,thehighpercentageofMHC-
restricted CD8
+ cells and their activation by cytokines
must also have decisive impact on the lytic capacity of
the whole effector cell population. This presumption is
supported by the fact that the cytotoxic activity of CIK
cellscanbepartiallyabrogatedbyblockageofMHCclass
I molecules on DCs with monoclonal antibodies (Märten,
unpublished data). Recent investigations and the results
presented here demonstrate that CIK cells can be stimu-
lated by autologous, non-pulsed monocyte-derived DCs
to exhibit significantly increased lytic activity against
various malignant cells such as pancreatic and colon
carcinoma cell lines, colon carcinoma cells derived from
patients [42] and patients’ AML cells. This activation de-
pends on the release of IL-12 by DCs upon coculture and
on direct cell-cell interactions during the coincubation
period, as coculture of DCs and effector cells performed
with cell culture inserts does not enhance CIK cell cyto-
toxic activity [43]. The reasons why AML cell lines used
in our experiments did not undergo enhanced lysis by
effector cells cocultured with DCs remain unclear.
Reversal of DC-mediated effector cell
activity
To explain the reduction in the DC-mediated cytotoxic ef-
fector cell activity against AML cells after pulsing of the
DCs with unfractionated antigens, inhibitory or toxic ef-
fects on the DCs of (parts of) the antigens have to be
assumed. Although we shortened the time of DC-antigen
contact to 4 hrs in some experiments, the impairment of
cytotoxic activity persisted. Obviously, even this period
commonly chosen for antigen exposure seems to be
sufficient for critical components to exhibit inhibitory or
toxiceffects.However,wecouldnotdetectmorphological,
significant numerical, or phenotypic alterations of the
DCs after antigen exposure (such as down-regulation of
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In any case, a loss of DC function may not explain the
reversal of target cell lysis to a value below the control
levels (effector cells not coincubated with DCs). Interest-
ingly, Schui et al. [44] also observed the mediation of in-
hibitory effects on cytotoxic T lymphocytes by blast cell
lysates from some of their AML patients used for pulsing
autologousDCs.Theypresumedundeterminedinhibitory
cytokines or TGF-β to be possibly responsible for this ef-
fect. This may also explain our observations in the allo-
geneic system when blast cell lysates were used. The re-
versal of target cell lysis after coculture with RNA-pulsed
DCs, however, needs further reflection. For toxic effects
of the transfectant could be excluded, we have to postu-
late, on the one hand, the MHC I-restricted presentation
of inhibitory peptides by the DCs after blast cell RNA in-
oculation and transcription. Our results implicate that
AMLcelllysatesandRNAeffectsmayhavetobecritically
distinguished from unfractionated antigens generated
from solid tumours.
Furthermore, the exhibition of immune escape mechan-
isms by a tumour (such as downregulation of MHC mo-
lecules or the lack of costimulatory molecules) helps it
to evade the host’s immune response and failure of tu-
mour cell recognition by T cells may occur when prior ex-
position to tumour-associated antigens happened in the
absenceofcostimulatoryfactors(suchasDCsexpressing
CD80 and CD86 on their surface) [45]. The use of DCs
in our experimental setting helped us to overcome this
mechanism. But, a lack of helper effects may also cause
theignoranceofantigens[46].Grohmannandcolleagues
demonstratedthatevenpresentationbyDCsofatumour-
associated antigen and ‘self-protein’ (P815AB from
murine mastocytoma cells) led to a transient and sus-
tained state of functional T cell non-responsiveness,
partially contributed to by a considerable decrease of
IFN-γ production by CD8
+ cells [47]. Hence, another
reasonforourobservationsmaybetheinductionofTcell
unresponsiveness. The underlying mechanisms of T cell
tolerance range from ignorance of the antigen to anergy
and clonal T cell deletion [48], [49], [50], [51]. We can
speculate that in our experiments the use of whole blast
cellproteinorRNAmayhaveledtoeffectorcelltolerance
and loss of target cell detection, for unfractionated AML
cell extracts may consist of proteins and sequences re-
cognizedas‘self-antigens’besidessomeleukemia-asso-
ciated antigens.
Concerning T cell unresponsiveness, IL-2 addition to the
cocultured T cells has been shown to be critical. On the
one hand, the stimulation of TH1 cells with high doses of
IL-2hasbeendemonstratedtoinducearefractoryperiod
during which the cells could not be stimulated by neither
antigen nor antigen-presenting cells in a murine model
[51]. Taking this into account, we varied the time point
of IL-2 addition to the T cells after coculture in order to
avoid early IL-2 receptor occupancy during antigen
presentation,butnoinfluenceontheeffectorcellactivity
couldbedetected.Ontheotherhand,highconcentrations
(300–1,000 U/mL) of the cytokine have been reported
topreventandreverseantigen-inducedunresponsiveness
in human T lymphocytes [52].
We and others have looked at the percentage of NKT
cellsandTregsinCIKcellpopulations.Tregscanbefound
in0–10%,NKTcellsinupto50%ofCIKcellcultures[40],
[53], [54]. Interestingly, dendritic cells reduce number
and function of CD4+CD25+ cells in cytokine-induced
killer cells [55].
It may be that some AML samples may be even able to
anergize DC activation by soluble factors. In future it may
be fruitful to identify such soluble factors.
Impact on clinical projects
We conclude that monocyte-derived DCs may be useful
in – allogeneic or autologous – vaccine strategies for the
treatment of AML as they can easily be generated from
PBMC in sufficient numbers and as we were able to
demonstrate their capacity to stimulate the cytotoxic
activity of lymphocytes against myelogenous leukemic
blasts. We achieved a target cell lysis comparable to that
obtained with leukemic blast-derived DCs and CTLs [56],
[57]. In contrast, according to our experiments the em-
ploymentofunfractionatedleukemia-antigensforarming
the DCs reduced cytotoxic effector cell activity and may
not be feasible for vaccine strategies in the treatment of
AML. Lysate concentrations and RNA quantities usually
usedforDC-basedcancervaccinesinsolidtumours[24],
[29] showed an inhibitory effect on the cytotoxic lympho-
cytes. Our data emphasize the necessity to search for
leukemia-associatedandleukemia-specificantigensand
their employment in future therapeutical strategies. For
instance,minorhistocompatibilityantigensHA-1andHA-2
havebeenshowntobeleukemia-associated(ratherthan
leukemia-specific) antigens to which HLA-identical T cell
responses could be induced by Mutis and colleagues
[58]. Maximal AML cell lysis could be achieved by using
peripheral blood-derived DCs pulsed with synthetic HA-1
and HA-2 to prime autologous HLA-A*0201-restricted
CTLs against leukemic cells from AML (and acute
lymphoblastic leukemia (ALL)) patients [31].
Our data are in accordance with observations from other
groups. PBSCs obtained for autologous stem cell trans-
plantation can constitute a novel source of MDCs to
design feasible vaccination trials [59], [60]. DC-based
vaccines against AML could be improved by CD25 T cell
depletion allowing the induction of a long-lasting T cell
response [61]. Dendritic cells pulsed or fused with AML
cellular antigen provided comparable in vivo antitumour
protective responses [62], [63].
Furthermore, adoptive immunotherapy strategies using
infusions of either autologous or allogeneic, ex vivo gen-
erated cytotoxic effector cells according to our protocol
couldbeatherapeuticaloption.Priorcoincubationand/or
simultaneous vaccination with non-pulsed DCs or with
DCs stimulated with defined leukemia-associated anti-
gens may help to optimize the antileukemic effect.
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